Valuation: Prothena Corporation plc

Market Cap 429M 391M 362M 326M 615M 40.07B 639M 4.37B 1.73B 21.63B 1.61B 1.57B 68.29B P/E 2026 *
-344x
P/E 2027 * -8.22x
Enterprise Value 429M 391M 362M 326M 615M 40.07B 639M 4.37B 1.73B 21.63B 1.61B 1.57B 68.29B EV / Sales 2026 *
5.92x
EV / Sales 2027 * 20.4x
Free-Float
75.93%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week+1.34%
Current month-1.53%
1 month-1.65%
3 months-10.23%
6 months-8.05%
Current year-12.67%
1 week 7.7
Extreme 7.7
8.67
1 month 7.7
Extreme 7.7
9.26
Current year 7.7
Extreme 7.7
11.8
1 year 7.7
Extreme 7.7
11.8
3 years 4.32
Extreme 4.32
41.54
5 years 4.32
Extreme 4.32
79.65
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
10/27/26 A Don 566,444 1.1034%
10/23/26 A Buy 50,000 0.0974%
10/14/26 A Buy 10,000 0.0195%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%+1.34%-16.52%-75.54% 429M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.70%-3.74%+7.02%+89.35% 58.93B
+0.45%+0.51%+26.40%+87.40% 55.21B
-0.16%-3.16%+13.85%+114.39% 46.1B
-0.72%-4.57%+18.97%+26.03% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
+2.11%-7.76%+130.64%+648.61% 34.57B
+0.83%-0.59%+77.31%+58.06% 32.46B
+1.04%+2.46%-40.57%+391.37% 26.28B
Average +0.05%-3.22%+29.20%+145.01% 40B
Weighted average by Cap. -0.03%-2.82%+34.26%+143.46%

Financials

2026 *2027 *
Net sales 72.42M 66.05M 61.07M 55.11M 104M 6.77B 108M 738M 292M 3.65B 272M 266M 11.53B 21.04M 19.18M 17.74M 16.01M 30.15M 1.97B 31.34M 214M 84.68M 1.06B 78.92M 77.26M 3.35B
Net income -1.38M -1.26M -1.17M -1.05M -1.98M -129M -2.06M -14.09M -5.57M -69.78M -5.19M -5.08M -220M -53.67M -48.95M -45.26M -40.84M -76.92M -5.02B -79.95M -547M -216M -2.71B -201M -197M -8.55B
Net Debt - -
Projected Income Statement - Annual - Prothena Corporation plc
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
19/11/26 $8.340 -0.12% 11,069
18/11/26 $8.350 +1.09% 764,266
17/11/26 $8.260 +3.64% 596,416
16/11/26 $7.970 -2.33% 318,708
13/11/26 $8.160 -0.85% 340,754
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Prothena Corporation plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.350USD
Average target price
21.40USD
Spread / Average Target
+156.29%
  1. Stock Market
  2. Stocks
  3. PRTA Stock